Prices delayed by at least 15 minutes | Print


Takeda Pharmaceutical Company Limited (TAK)

American Depository Receipts
Sell: $13.01|Buy: $13.53|Change: 0.16 (-1.21%)

Open 

$13.15


Previous close 

$13.23


Trade high 

$13.19


Volume 

1,697,132


Year high 

$17.11


Year low 

$13.05


Dividend yield 

4.75%


Market capitalisation 

$41.01 bn


P/E ratio 

36.43


ISIN 

US8740602052


This share can be held in a Dealing accountISALifetime ISAJISASIPP

Share price

Dividends

PreviousLatest
Record date31/03/202329/09/2023
Ex-dividend date30/03/202328/09/2023
Payment date10/07/202311/12/2023
Amount$0.30996$0.319068

Performance 25/04/2024

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann


Total return (%)
Takeda Pharmaceutical Company Limited- 1.21
More...

Company profile

Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4 trillion in fiscal 2022. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the U.S., 20% from Japan, 20% from Europe and Canada.

Sector 

Healthcare


AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2024 AJ Bell. All rights reserved.